1. Álvarez C, Gómez E, Simón M et al. Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake. Eur J Clin Pharmacol 2012; 68 (7): 1043–7.
2. Van Zwieten PA. The pharmacological properties of lipophilic calcium antagonists. Blood Press (Suppl.) 1998; 2: 5–9.
3. Corsini A, Accomazzo MR, Canavesi M et al. The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved? Blood Press (Suppl.) 1998; 2: 18–22.
4. Guarneri L, Angelico P, Ibba M et al. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittelforschung 1996; 46 (1): 15–24.
5. Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment of severe essential hypertension. J Cardiovasc Pharmacol 1997; 29: 50–3.
6. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998; 16: 1831–8.
7. Cafiero M, Giasi M. Long-term treatment with lercanidipine in patients with mild and moderate hypertension. J Cardiovasc Pharmacol 1997; 29: 45–9.
8. Circo A. Active dose findings in a double-blind placebo-controlled design in patients with mild and moderatehypertension. J Cardiovasc Pharmacol 1997; 29: 21–5.
9. Giorgio L. Viviani. Lercanidipine in Type II Diabetic Patients With Mild to Moderate Arterial Hypertension. J Cardiovasc Pharmacol 2002; 40: 133–9.
10. Cleophas TJ, van Ouwerkerk BM, van der Meulen J, Zwinderman AH. Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies. Angiology 2001; 52 (7): 469–75.
11. Romito R, Pansini MI, Perticone F et al. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich) 2003; 5 (4): 249–53.
12. Bargallo Sangiorgi G, Putignano E, Calcara L et al. Efficacy and tolerability of lercanidipine vs captopril in patients with mild and moderate hypertension in a double-blind controlled study. J Cardiovascul Pharmacol 1997; 29: 36–9.
13. James IG, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002; 16 (8): 605–10.
14. McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs 2000; 60 (5): 1123–40.
15. Campo C, Saavedra J, Segura J et al. Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial. Minerva Med 2005; 96 (5): 365–71.
16. Taddei S, Virdis A, Ghiadoni L et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003; 41 (4): 950–5.
17. Grassi G, Quarti-Trevano F, Scopelliti F et al. Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes. Blood Press 2006; 15 (5): 268–74.
18. Menne J, Park JK, Agrawal R et al. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. Faseb J 2006; 20 (7): 994–6.
19. Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004; 17 (5): 259–66.
20. Poncelet P, Ribstein J, Goullard L et al. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. Ann Cardiol Angeiol (Paris) 2004; 53 (3): 123–30.
21. Ninci MA, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997; 29: S40–4.
22. Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging (Milano) 2000; 12 (5): 375–9.
23. Mackenzie IS, McEniery CM, Dhakam Z et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54 (2): 409–13.
24. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002; 11 (2): 95–100.
25. Hollenberg NK. Observations on the safety of lercanidipine: adverse event data from placebo-controlled trials. Am J Hypertens 2002; 15: 58A–59A.
26. Leonetti G, Magnani B, Pessina AC et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15 (11): 932–40.
27. Borghi C, Prandin MG, Dormi A, Ambrosioni E. Study group of the regional Unit of the Italian Society of Hypertension. 2003. Improved Tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press (Suppl. 1): 14–21.
28. Burnier M, Gasser UE. Effi cacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother 2007; 8: 2215–23.

Л.О.Минушкина

ФГБУ Учебно-научный медицинский центр УД Президента РФ, Москва